Breast cancer is the most commonly diagnosed cancer and the second leading cause of cancer-related death for women in the United States. Current guidelines by the National Comprehensive Cancer Network and American Society of Clinical Oncology recommend management with endocrine therapy,
ERBB2- (formerly
HER2-) (OMIM 164870) directed therapy, radiotherapy, and cytotoxic chemotherapy or a combination for patients with invasive breast cancer.
1 The choice of treatment modality depends on patient and tumor characteristics, expression of hormone receptors (HR; including estrogen receptor α [ER] or progesterone receptor [PR]), and
ERBB2 status as well as genomic test results such as the Oncotype DX breast recurrence score.
2 Endocrine therapy with a duration of 5 to 10 years is a standard of care for HR-positive disease, which accounts for approximately 70% of all breast cancers.
3-5 Radiotherapy applies to all individuals who underwent breast-conserving surgery and may be used for patients with a tumor larger than 5 cm or with node-positive disease after mastectomy. Chemotherapy is recommended for patients with
ERBB2-positive and HR-negative tumors, node-positive disease, and high Oncotype recurrence scores in HR-positive and
ERBB2-negative breast cancer.
3,6